Merck & Co. Inc. (MRK)

72.35
NYSE : Health Technology
Prev Close 72.21
Day Low/High 71.94 / 72.66
52 Wk Low/High 52.83 / 72.89
Avg Volume 8.23M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 192.04B
EPS 0.90
P/E Ratio 144.42
Div & Yield 1.92 (2.67%)

Latest News

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck's KEYTRUDA® (pembrolizumab) Showed A Complete Response Rate Of Nearly 40 Percent In Patients With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Standard Of Care

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients...

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

You Need a Game Plan: Cramer's 'Mad Money' Recap (Friday 10/19/18)

Jim Cramer is ready to call the Fed out. And he has your game plan ready for next week.

This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

This Market Needs More Fear: Cramer's 'Mad Money' Recap (Thursday 10/18/18)

Jim Cramer says there's still too much greed and complacency, and not enough fear and panic.

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck's KEYTRUDA® (pembrolizumab) In Combination With Pfizer's Inlyta® (axitinib) Significantly Improved Overall Survival (OS) And Progression-free Survival (PFS) As First-Line Therapy For Advanced Or Metastatic Renal Cell Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Inlyta ® (axitinib), Pfizer's...

Merck Announces Appointment Of Jim Scholefield As Chief Information And Digital Officer

Merck Announces Appointment Of Jim Scholefield As Chief Information And Digital Officer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct.

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation For Pancreatic Cancer

U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation For Pancreatic Cancer

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck To Hold Third-Quarter 2018 Sales And Earnings Conference Call On October 25

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.

Up To 10-Years Of Follow-up Data Reaffirm Safety Profile Of Investigational Cladribine Tablets

Up To 10-Years Of Follow-up Data Reaffirm Safety Profile Of Investigational Cladribine Tablets

DARMSTADT, Germany, October 10, 2018 /PRNewswire/ -- Real-world evidence and longer clinical trial follow-up show no i ncreased incidence of serious adverse events  Additional post-hoc data analyses support s ustained efficacy of c ladribine t ablets in...

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck's Broad Oncology Pipeline To Be Highlighted At ESMO 2018 Congress

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from Merck's broad oncology portfolio and robust early pipeline will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in...

New Efficacy And Safety Data On MS Portfolio To Be Presented At ECTRIMS 2018

New Efficacy And Safety Data On MS Portfolio To Be Presented At ECTRIMS 2018

DARMSTADT, Germany, Oct. 8, 2018 /PRNewswire/ -- Late-breaking Phase II primary endpoint data  for investigational therapy evobrutinib, the first oral BTK inhibitor to show clinical proof-of-concept in RMS Up to 10 years of patient experience provides...

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck Announces Week 96 Data From Pivotal Phase 3 DRIVE-AHEAD Study Evaluating DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) For The Treatment Of HIV-1 In Treatment-Naïve Patients

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new results from the Phase 3 DRIVE-AHEAD clinical trial evaluating the efficacy and safety of DELSTRIGO™, a once-daily fixed-dose combination tablet of doravirine (100...

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck's HIV Therapy DELSTRIGO™ (doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) Meets Primary Efficacy Endpoint In Phase 3 DRIVE-SHIFT Study Evaluating Switch To DELSTRIGO From Other Antiretroviral Treatment Regimens

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO™, a once-daily fixed-dose combination tablet of...

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck Announces "Safer Childbirth Cities" Initiative, Issues Call To Action To Reverse The Rise In U.S. Maternal Deaths

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today a new effort to support cities across the country to help women have a healthy pregnancy and safe childbirth.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its CEO to hear about her journey and how immunotherapies are taking the lead.

The New #13 Most Shorted Dow Component: Merck

The New #13 Most Shorted Dow Component: Merck

The most recent short interest data has been released for the 09/14/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck Board Rescinds Mandatory CEO Retirement Policy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that its Board of Directors has rescinded its policy subjecting the company's Chief Executive Officer to mandatory retirement at age 65.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck Receives Positive CHMP Opinion For DELSTRIGO™ (doravirine/lamivudine/tenofovir Disoproxil Fumarate) And PIFELTRO™ (doravirine) In The European Union For The Treatment Of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing...

Merck Publishes Corporate Responsibility Report

Merck Publishes Corporate Responsibility Report

Report Illustrates How Merck Creates Sustainable Value for Business and Society

Merck and PPL Corp. Still Look Good Here

Both names have enjoyed recent price run-ups and continue to pay decent dividends.

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival In Previously Untreated Patients With Advanced Renal Cell Carcinoma In Phase III Study

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival In Previously Untreated Patients With Advanced Renal Cell Carcinoma In Phase III Study

DARMSTADT, Germany and NEW YORK, Sept. 11, 2018 /PRNewswire/ -- Not intended for UK-based media First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type Results significant in PDL1+ and all-comer...

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) In Combination With Pemetrexed And Platinum Chemotherapy For The First-Line Treatment Of Patients With Metastatic Nonsquamous NSCLC, With No EGFR Or ALK Genomic Tumor Aberrations

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, in combination with pemetrexed (ALIMTA ®) and platinum chemotherapy for the...

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C.

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Data From Merck's Leading Lung Cancer Research Program With KEYTRUDA® (pembrolizumab) To Be Presented At IASLC 19th World Conference On Lung Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that investigational data from the company's leading lung cancer research program with KEYTRUDA, Merck's anti-PD-1 therapy, will be presented at the IASLC 19th World...

TheStreet Quant Rating: B+ (Buy)